Value of NGS in Oncology
As genomics-focused pharmacology begins to play a greater role in cancer treatment, next-generation sequencing (NGS) has emerged as a valuable method for obtaining a deeper and more accurate look into the molecular underpinnings of individual tumors. With targeted therapies becoming the new standard of care in oncology, NGS-driven companion diagnostics are widely seen as driving the selection of treatments to optimize patient outcomes in the future.
Compared to traditional methods, NGS offers advantages in accuracy, sensitivity, and speed that has the potential to make a significant impact on the field of oncology. Because NGS can assess multiple genes in a single assay, it eliminates the need to order multiple tests to identify the causative mutation.
This multigene approach decreases the time to answer, providing a more economical solution and reducing the risk of exhausting precious clinical samples. In addition, NGS can provide high sensitivity, enabling the detection of mutations present at as little as 5% of the DNA isolated from a tumor sample.
NGS has the potential to change the future of oncology and advance the promise of personalized medicine. We invite you to learn more by examining the resources collected here.
Introduction to NGS in Oncology
Learn more about how NGS technology works and the advantages it offers over traditional methods in these in-depth introductions tailored to oncologists and molecular pathologists.
The FDA Grants Breakthrough Device Designation
In January, Illumina received exciting news about the opportunity to expedite FDA approval for breakthrough technologies. Read the announcement to see what it means for the TruSight Oncology assay.
Read Article
Comprehensive Genomic Profiling (CGP)
This next-generation sequencing approach consolidates hundreds of cancer-related biomarkers, including different variant types, into a single assay. Explore the benefits and find out how it compares to other common cancer NGS methods.
Learn More About CGP
Recent Oncology News & Interviews
A Golden Age for China’s NGS Industry
At Illumina’s first NGS Summit in Shanghai, genomics leaders discuss the future of oncology and healthcare
Read Article
The Changing Landscape of NGS Implementation in Molecular Diagnostic Laboratories
Key opinion leaders discuss the ongoing challenges and potential of NGS in oncology testing.
Read Interview
NEJM Study Shows WGS Improves Molecular Profiling
Side-by-side comparison shows WGS produced more accurate results in less time and at a similar cost
Read ArticleMore Cancer-Related NGS Methods
Tumor Mutational Burden (TMB)
NGS can help clinical cancer researchers estimate TMB, identify neoantigens, and study innovative therapies to boost the immune response.
Learn MorectDNA Sequencing
NGS offers the sensitivity and specificity that clinical researchers need to detect low levels of circulating tumor DNA (ctDNA) in the bloodstream.
Learn MoreCancer Epigenetics
Explore the benefits of NGS and microarrays for analyzing altered methylation patterns and other epigenetic changes in cancer.
Learn MoreInterested in receiving newsletters, case studies, and information on cancer genomics? Enter your email address.
Learn More
Genomic Applications in Oncology
The Medical Affairs team at Illumina discusses the applications of genomics in oncology for risk prediction and precision medicine.
Francis deSouza Speaks at Aspen Ideas: Health
Francis deSouza, President and CEO of Illumina, shares his views on actions needed to bring genomics to the patients who need it.
Medical Genetics Education
Find educational resources about medical genetics and learn how genomic information can be used in clinical practice.
